Aghajanian, G. K. & Marek, G. J. (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research Reviews, 31, 302–312.
Anand, A., Charney, D. S., Oren, D. A.
et al (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Archives of General Psychiatry, 57, 270–276.
Andreasen, N. C., Arndt, S., Alliger, R.
et al (1995) Symptoms of schizophrenia. Methods, meanings, and mechanisms. Archives of General Psychiatry, 52, 341–351.
Anis, N. A., Berry, S. C., Burton, N. R.
et al (1983) The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate. British Journal of Pharmacology, 79, 565–575.
Berman, R. M., Cappiello, A., Anand, A.
et al (2000) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47, 351–354.
Boyer, P. A., Skolnick, P. & Fossom, L. H. (1998) Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridisation study. Journal of Molecular Neuroscience, 10, 219–233.
Bressan, R. A. & Pilowsky, L. S. (2000) Imaging the glutamatergic system in vivo – relevance to schizophrenia. European Journal of Nuclear Medicine, 27, 1723–1731.
Calabrese, J. R., Bowden, C. L., Sachs, G. S.
et al (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Journal of Clinical Psychiatry, 60, 79–88.
Carlsson, A., Hansson, L. O., Waters, N.
et al (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sciences, 61, 75–94.
Carlsson, A., Hansson, L. O., Waters, N.
et al (1999) A glutamatergic deficiency model of schizophrenia. British Journal of Psychiatry
174 (suppl. 37), 2–6.
Carlsson, A., Waters, N., Holm-Waters, S.
et al (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Reviews of Pharmacology and Toxicology, 41, 237–260.
Davis, M., Rainnie, D. & Cassell, M. (1994) Neurotransmission in the rat amygdala related to fear and anxiety. Trends in Neurosciences, 17, 208–214.
Farber, N. B., Hanslick, J., Kirby, C.
et al (1998) Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology, 18, 57–62.
Goff, D. C. & Wine, L. (1977) Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research, 27, 157–168.
Goff, D. C., Tsai, G., Levitt, J.
et al (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry, 56, 21–27.
Grotta, J., Clark, W., Coull, B.
et al (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischaemic stroke. Results of a phase IIa randomised trial. Stroke, 26, 602–605.
Hansson, L. O., Waters, N., Winblad, B.
et al (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortem brain tissue. Journal of Neural Transmission, 98, 217–235.
Heresco-Levy, U., Javitt, D. C. & Ermilov, M. (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms. Archives of General Psychiatry, 56, 29–36.
Javitt, D. C. & Zukin, S. R. (1991) Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301–1308.
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y.
et al (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry, 48, 627–640.
Krystal, J. H., Karper, L. P., Seibyl, J. P.
et al (1994) Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199–214.
Krystal, J. H., Abi-Dargham, A., Laruelle, M.
et al (1999a) Pharmacologic model of psychoses. In Neurobiology of Mental Illness (eds Charney, D. S., Nestler, E. & Bunney, B. S.) pp. 214–224. New York: Oxford University Press.
Krystal, J. H., D'Souza, D. C., Karper, L. P.
et al (1999b) Interactive effects of subanaesthetic ketamine and haloperidol. Psychopharmacology, 145, 193–204.
Krystal, J. H., D'Souza, D. C., Sanacora, G.
et al (2001) Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. Medical Clinics of North America, 85, 559–577.
Laruelle, M., Abi-Dargham, A., van Dyck, C. H.
et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93, 9235–9240.
Leveque, J.-C., Macias, W., Rajadhyasksha, A.
et al (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. The Journal of Neuroscience, 20, 4011–4020.
Marek, G. J., Wright, R. A., Schoepp, D. D.
et al (2000) Physiological antagonism between 5-hydroxy-tryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics, 292, 76–87.
Martin, P., Waters, N., Schmidt, C. J.
et al (1998) Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. Journal of Neural Transmission, 105, 365–396.
Meador-Woodruff, J. H. & Healy, D. J. (2000) Glutamate receptor expression in schizophrenic brain. Brain Research – Brain Research Reviews, 31, 288–294.
Moghaddam, B., Adams, B., Verma, A.
et al (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience, 17, 2921–2927.
Moghaddam, B. & Adams, B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 281, 1349–1352.
Morgan, C. A. R., Grillon, C., Southwick, S. M.
et al (1995) Fear-potentiated startle in post-traumatic stress disorder. Biological Psychiatry, 38, 378–385.
Newcomer, J. W., Farber, N. B., Jevtovic-Todorovic, V.
et al (1999) Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology, 20, 106–118.
Olney, J. W., Wozniac, D. F. & Farber, N. B. (1997) Excitotoxic neurodegeneration in Alzheimer's disease: new hypothesis and new therapeutic strategies. Archives of Neurology, 54, 1234–1240.
Paul, I. A., Nowak, G., Layer, R. T.
et al (1994) Adaptation of N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics, 269, 95–102.
Pilowsky, L. S., Costa, D. C., Ell, P. J.
et al (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I-IBZM SPET study. Psychological Medicine, 23, 791–797.
Schoepp, D. D., Jane, D. E. & Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 38, 1431–1476.
Tamminga, C. A. (1998) Schizophrenia and glutamate. Critical Reviews in Neurobiology, 12, 21–36.
Tamminga, C. A., Thaker, G. K., Buchanan, R.
et al (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry, 49, 522–530.
Tekin, S., Aykut-Bingol, C., Tanridag, T.
et al (1998) Antiglutamatergic therapy in Alzheimer's disease: effects of lamotrigine. Journal of Neural Transmission, 105, 295–303.
Tsai, G., Yang, P., Chung, L. C.
et al (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 44, 1081–1089.